

MPNs and GVHD

		Clinical Proof of Concept	Pivotal	Approved
Jakafi® (ruxolitinib) ¹ JAK1/JAK2	Myelofibrosis ² , polycythemia vera ² , GVHD ²			
ruxolitinib XR (QD) JAK1/JAK2	Bioequivalence and stability testing			
axatilimab ³ CSF-1R	Chronic GVHD			
zilurgisertib ALK2	Anemia due to hematological disorders including MF ± ruxolitinib			
INCB57643 BET	Myelofibrosis ± ruxolitinib			
INCA33989 mutCALR	Myelofibrosis, essential thrombocythemia ± ruxolitinib			

Dermatology and Other IAI

Opzelura® (ruxolitinib) cream JAK1/JAK2	AD ² , vitiligo ^{2,4}			
ruxolitinib cream JAK1/JAK2	Pediatric AD, prurigo nodularis			
	Hidradenitis suppurativa, lichen planus, lichen sclerosus			
povorcitinib JAK1	Hidradenitis suppurativa, vitiligo			
	Prurigo nodularis, chronic spontaneous urticaria, asthma			
zilurgisertib ALK2	Fibrodysplasia ossificans progressiva			

Partnered Programs

Olumiant® (baricitinib) ⁵ JAK1/JAK2	Rheumatoid arthritis ⁶ , COVID-19 ⁶ , AD ^{4,7} , alopecia areata ^{2,4,7}			
Tabrecta® (capmatinib) ⁸ MET	NSCLC with METex14 ⁶			
capmatinib ⁸ MET	Liver cancer			

General Hematology/Oncology

		Clinical Proof of Concept	Pivotal	Approved
Pemazyre® (pemigatinib) FGFR1/2/3	2L+ cholangiocarcinoma ⁹ , MLNs with FGFR1 rearrangement ^{2,7}			
Monjuvi® (tafasitamab-cxix) ¹⁰ Minjuvi® (tafasitamab) ¹⁰ CD19	r/r DLBCL ^{2,4,11}			
Iclusig® (ponatinib) ¹² BCR-ABL	Chronic myeloid leukemia ⁴ , Ph+ ALL ⁴			
Zynyz® (retifanlimab-dlwr) ¹³ PD-1 (mAb)	Merkel cell carcinoma ²			
pemigatinib FGFR1/2/3	1L cholangiocarcinoma			
	Glioblastoma			
tafasitamab ¹⁰ CD19	1L DLBCL, r/r follicular lymphoma, r/r MZL			
retifanlimab ¹³ PD-1 (mAb)	Squamous cell anal carcinoma, NSCLC			
	MSI-H endometrial cancer			
itacitinib JAK1	Cytokine release syndrome			
INCB99280 PD-L1 (small molecule)	Cutaneous squamous cell carcinoma, solid tumors			
INCB99318 PD-L1 (small molecule)	Solid tumors			
INCAGN2385 ¹⁴ LAG-3	Solid tumors			
INCAGN2390 ¹⁴ TIM-3	Solid tumors			
INCA32459 ¹⁵ LAG-3×PD-1	Advanced malignancies			
INCA33890 ¹⁵ TGFβR2×PD-1	Solid tumors			
INCB123667 CDK2	Solid tumors			

17 Molecular Targets

22 Clinical Compounds

8 Approved Products

Updated as of October 31, 2023

Please refer to local prescribing information for more information, including full safety information, on Incyte's marketed medicines, or on medicines marketed by Incyte's collaboration partners.

1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax 4. Approved in Europe 5. Worldwide rights to baricitinib licensed to Lilly 6. Approved in multiple territories globally 7. Approved in Japan 8. Worldwide rights to capmatinib licensed to Novartis 9. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 10. Development in collaboration with MorphoSys and co-commercialization in the U.S. with MorphoSys; exclusive commercialization rights held by Incyte outside the U.S. 11. Approved in Canada 12. European rights to Iclusig licensed from Takeda 13. Licensed from MacroGenics 14. Discovery collaboration with Agenus 15. Development in collaboration with Merus

1L, first-line; 2L+, second-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; mAb, monoclonal antibody; MF, myelofibrosis; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; MSI-H, microsatellite instability-high; MZL, marginal zone lymphoma; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory; XR, extended release.